ID29891A - Penggunaan triazol terfluorinasi untuk mengobati rasa sakit dan gangguan-gangguan yang berhubungan dengan kasih-sayang dan perhatian - Google Patents

Penggunaan triazol terfluorinasi untuk mengobati rasa sakit dan gangguan-gangguan yang berhubungan dengan kasih-sayang dan perhatian

Info

Publication number
ID29891A
ID29891A IDW00200101864A ID20011864A ID29891A ID 29891 A ID29891 A ID 29891A ID W00200101864 A IDW00200101864 A ID W00200101864A ID 20011864 A ID20011864 A ID 20011864A ID 29891 A ID29891 A ID 29891A
Authority
ID
Indonesia
Prior art keywords
attention
disorders
fluorinated
love
triazol
Prior art date
Application number
IDW00200101864A
Other languages
English (en)
Inventor
Markus Schmutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/259,911 external-priority patent/US6054471A/en
Priority claimed from US09/259,910 external-priority patent/US6156775A/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ID29891A publication Critical patent/ID29891A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IDW00200101864A 1999-03-01 2000-02-28 Penggunaan triazol terfluorinasi untuk mengobati rasa sakit dan gangguan-gangguan yang berhubungan dengan kasih-sayang dan perhatian ID29891A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/259,911 US6054471A (en) 1999-03-01 1999-03-01 Use of fluorinated triazoles in treating neuropathic pain
US09/259,910 US6156775A (en) 1999-03-01 1999-03-01 Use of fluorinated triazoles in treating affective and attention disorders

Publications (1)

Publication Number Publication Date
ID29891A true ID29891A (id) 2001-10-18

Family

ID=26947613

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101864A ID29891A (id) 1999-03-01 2000-02-28 Penggunaan triazol terfluorinasi untuk mengobati rasa sakit dan gangguan-gangguan yang berhubungan dengan kasih-sayang dan perhatian

Country Status (25)

Country Link
EP (2) EP1609505B1 (id)
JP (1) JP4700195B2 (id)
KR (2) KR100839765B1 (id)
CN (2) CN1636562A (id)
AT (1) ATE303179T1 (id)
AU (1) AU764508B2 (id)
BR (1) BR0008606A (id)
CA (1) CA2362411C (id)
CY (1) CY1115241T1 (id)
DE (1) DE60022317T2 (id)
DK (2) DK1156856T3 (id)
ES (2) ES2441208T3 (id)
HK (1) HK1086775A1 (id)
HU (2) HU227602B1 (id)
ID (1) ID29891A (id)
IL (3) IL144852A0 (id)
NO (2) NO328927B1 (id)
NZ (1) NZ513716A (id)
PL (2) PL199660B1 (id)
PT (1) PT1609505E (id)
RU (1) RU2238725C2 (id)
SI (1) SI1609505T1 (id)
SK (2) SK286775B6 (id)
TW (1) TW513301B (id)
WO (1) WO2000051577A2 (id)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2905878T3 (es) 2015-01-30 2022-04-12 Neurocrine Biosciences Inc Triazoles sustituidos y métodos relacionados con los mismos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1511195A (en) * 1976-10-18 1978-05-17 Ici America Inc Triazole derivatives
FI93544C (fi) * 1985-04-18 1995-04-25 Ciba Geigy Ag Menetelmä fluorattujen, antikonvulsiivisesti vaikuttavien 1-bentsyyli-1H-1,2,3-triatsoliyhdisteiden valmistamiseksi

Also Published As

Publication number Publication date
HU1000576D0 (en) 2010-12-28
EP1609505A1 (en) 2005-12-28
HU230044B1 (hu) 2015-05-28
PL199660B1 (pl) 2008-10-31
NO20014180D0 (no) 2001-08-28
CA2362411C (en) 2009-11-24
RU2238725C2 (ru) 2004-10-27
AU3425300A (en) 2000-09-21
JP2002538100A (ja) 2002-11-12
CN1636562A (zh) 2005-07-13
KR20080003944A (ko) 2008-01-08
KR100839766B1 (ko) 2008-06-20
SI1609505T1 (sl) 2014-03-31
SK286775B6 (sk) 2009-05-07
KR100839765B1 (ko) 2008-06-20
SK12252001A3 (sk) 2002-05-09
DE60022317T2 (de) 2006-06-01
DK1156856T3 (da) 2005-10-31
DK1609505T3 (en) 2014-02-17
KR20010108285A (ko) 2001-12-07
PT1609505E (pt) 2014-02-24
CN1356916A (zh) 2002-07-03
CY1115241T1 (el) 2017-01-04
EP1156856A2 (en) 2001-11-28
TW513301B (en) 2002-12-11
ES2244413T3 (es) 2005-12-16
NO20014180L (no) 2001-08-28
ES2441208T3 (es) 2014-02-03
HK1086775A1 (en) 2006-09-29
EP1609505B1 (en) 2013-12-11
HUP0302780A2 (hu) 2003-12-29
AU764508B2 (en) 2003-08-21
NO334104B1 (no) 2013-12-09
JP4700195B2 (ja) 2011-06-15
NO20092921L (no) 2001-08-28
PL197158B1 (pl) 2008-03-31
NZ513716A (en) 2003-10-31
PL350418A1 (en) 2002-12-16
WO2000051577A2 (en) 2000-09-08
HU227602B1 (en) 2011-09-28
ATE303179T1 (de) 2005-09-15
SK286203B6 (sk) 2008-05-06
WO2000051577A3 (en) 2001-01-25
BR0008606A (pt) 2002-01-22
DE60022317D1 (de) 2005-10-06
CA2362411A1 (en) 2000-09-08
IL144852A0 (en) 2002-06-30
NO328927B1 (no) 2010-06-14
HUP0302780A3 (en) 2004-10-28
IL189190A0 (en) 2008-06-05
IL144852A (en) 2008-11-26
EP1156856B1 (en) 2005-08-31
CN1195516C (zh) 2005-04-06

Similar Documents

Publication Publication Date Title
ATE207351T1 (de) Verwendung vonmodafinil zur behandlung von atemstillstand im schlaf und zentral erregten atembeschwerden
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
ATE186834T1 (de) Verwendung von wirksamen mengen von aktiven stoffen zur behandlung von mischhaut
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE69902520D1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
NO20006506D0 (no) Anvendelse av valproinsyreanalog for behandlingen og forebyggelsen av migrene og affektive sykdommer
ID29891A (id) Penggunaan triazol terfluorinasi untuk mengobati rasa sakit dan gangguan-gangguan yang berhubungan dengan kasih-sayang dan perhatian
ATE287713T1 (de) Verwendung von riluzol zur behandlung multipler sklerose
PT1133296E (pt) Nova aplicacao terapeutica da nicergolina
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60228988D1 (de) Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE69919578D1 (de) VERWENDUNG von NIEDERMOLEKULAREM HEPARIN zur Behandlung und/oder Prophylaxe motoneuronaler Krankheiten
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
ATE216884T1 (de) Verwendung von sulbutiamin zur behandlung von psychomotorischen oder psychointellektuellen beschwerden
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
DE60128130D1 (de) Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a
ZA200107138B (en) Use of fluorinated triazoles for treating pain and affective or attention disorders.
ATE302605T1 (de) Tazaroten und uvb-phototherapie zur behandlung von psoriasis
PT1133297E (pt) Nova aplicacao terapeutica da 1,6-dimetil-8beta-hidroximetil-10alfa-metoxiergolina
AU2013219147B2 (en) Uses of DPP-IV inhibitors